Summit Therapeutics Inc. announced on June 30, 2025, a clinical collaboration with Revolution Medicines, Inc. to evaluate ivonescimab in combination with three of Revolution Medicines’ RAS(ON) inhibitors. This collaboration will explore combinations in RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC).
Under the terms, Summit will supply ivonescimab for the clinical research, with Revolution Medicines serving as the study sponsor. Both companies will retain commercial rights to their respective compounds, and the agreement is mutually non-exclusive, aiming to improve outcomes for patients with these challenging cancers.
Additionally, Summit Therapeutics Inc. was added to the Russell Midcap Growth Index, Russell 1000 Dynamic Index, and Russell 1000 Index. Concurrently, the company was dropped from several Russell small-cap indices, including the Russell 2000 Index, reflecting a shift in its market capitalization classification.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.